Literature DB >> 9059395

Brain lesion contrast in MR imaging. Dependence on field strength and concentration of gadodiamide injection in patients and phantoms.

P Akeson1, B Vikhoff, F Ståhlberg, S Holtås.   

Abstract

PURPOSE: To compare the contrast effects of gadodiamide injection at 0.3 and at 1.5 T, at different concentrations in phantoms, and to correlate the results to clinical doses used for examining brain lesions.
MATERIAL AND METHODS: Gel phantoms with T1 and T2 corresponding to brain gray matter were doped with different concentrations of gadodiamide injection and examined with T1-weighted sequences. Two different sets of phantoms were used, one for 0.3 T and one for 1.5 T. To express contrast, a quotient (RATIOphantom) between signals in each tube with gadodiamide injection and in the one without it was calculated. A corresponding quotient (RATIOpatient) between signals in brain metastases and in gray matter was calculated in 16 patients examined at 0.3 T (0.1 and 0.3 mmol Gd/kg b.w.) and in 5 patients examined at 1.5 T (0.1 mmol Gd/kg b.w.).
RESULTS: Maximum RATIOphantom and RATIOpatient were more than 50% higher at 1.5 T than at 0.3 T at equal concentrations using heavily T1-weighted sequences. The use of SE TR/TE 600/30 instead of 400/25 reduced the contrast effect 15-45% depending on concentration. Comparing RATIOpatient to RATIOphantom suggests that the maximum T1 effect of Gd contrast media occurs at higher doses than in current clinical use, as at 0.1 mmol/kg b.w. we achieved 38% (0.3 T) and 56% (1.5 T) of the maximum phantoms. At 0.3 mmol/kg b.w. we achieved 63% (0.3 T) of the theoretical maximum.
CONCLUSION: The contrast effect of Gd contrast media is higher at 1.5 T than at 0.3 T. Higher doses than presently used might prove useful especially at lower field strengths where the contrast effect of Gd is less pronounced. Heavy T1-weighting is also important.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9059395     DOI: 10.1080/02841859709171235

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  7 in total

Review 1.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

Review 2.  The optimal use of contrast agents at high field MRI.

Authors:  Siegfried Trattnig; Kathia Pinker; Ahmed Ba-Ssalamah; Iris-Melanie Nöbauer-Huhmann
Journal:  Eur Radiol       Date:  2006-03-01       Impact factor: 5.315

3.  Emerging techniques and technologies in brain tumor imaging.

Authors:  Benjamin M Ellingson; Martin Bendszus; A Gregory Sorensen; Whitney B Pope
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

4.  Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trials.

Authors:  Rebecca A Packer; John H Rossmeisl; Michael S Kent; John F Griffin; Christina Mazcko; Amy K LeBlanc
Journal:  Vet Radiol Ultrasound       Date:  2018-03-09       Impact factor: 1.363

5.  [Use of contrast agent in high-field MRI (3 T)].

Authors:  S Trattnig; A Ba-Ssalamah; I M Nöbauer-Huhmann; M Barth; K Pinker; V Mlynarik
Journal:  Radiologe       Date:  2004-01       Impact factor: 0.635

Review 6.  Radiogenomic Predictors of Recurrence in Glioblastoma-A Systematic Review.

Authors:  Felix Corr; Dustin Grimm; Benjamin Saß; Mirza Pojskić; Jörg W Bartsch; Barbara Carl; Christopher Nimsky; Miriam H A Bopp
Journal:  J Pers Med       Date:  2022-03-04

7.  Brain tumours at 7T MRI compared to 3T--contrast effect after half and full standard contrast agent dose: initial results.

Authors:  Iris-Melanie Noebauer-Huhmann; P Szomolanyi; C Kronnerwetter; G Widhalm; M Weber; S Nemec; V Juras; M E Ladd; D Prayer; S Trattnig
Journal:  Eur Radiol       Date:  2014-09-07       Impact factor: 5.315

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.